SynAct Pharma AB (SYNACT) - Total Liabilities
Based on the latest financial reports, SynAct Pharma AB (SYNACT) has total liabilities worth Skr58.76 Million SEK (≈ $6.32 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash efficiency ratio of SynAct Pharma AB to assess how effectively this company generates cash.
SynAct Pharma AB - Total Liabilities Trend (2014–2024)
This chart illustrates how SynAct Pharma AB's total liabilities have evolved over time, based on quarterly financial data. Check SYNACT cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
SynAct Pharma AB Competitors by Total Liabilities
The table below lists competitors of SynAct Pharma AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Vascon Engineers Limited
NSE:VASCONEQ
|
India | Rs10.70 Billion |
|
Kestrel Group, Ltd.
NYSE:KG
|
USA | $986.67 Million |
|
Shanghai Huili Building Materials Co Ltd
SHG:900939
|
China | $35.67 Million |
|
Mobiletron Electronics Co Ltd
TW:1533
|
Taiwan | NT$5.87 Billion |
|
Vranken-Pommery Monopole Société Anonyme
PA:VRAP
|
France | €927.49 Million |
|
CLERHP Estructuras S.A
MC:CLR
|
Spain | €74.25 Million |
|
Caravel Minerals Ltd
AU:CVV
|
Australia | AU$901.04K |
|
MEI Pharma Inc
NASDAQ:MEIP
|
USA | $1.35 Million |
Liability Composition Analysis (2014–2024)
This chart breaks down SynAct Pharma AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see SynAct Pharma AB market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.28 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.30 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SynAct Pharma AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SynAct Pharma AB (2014–2024)
The table below shows the annual total liabilities of SynAct Pharma AB from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr56.35 Million ≈ $6.06 Million |
+8.72% |
| 2023-12-31 | Skr51.83 Million ≈ $5.58 Million |
+222.42% |
| 2022-12-31 | Skr16.08 Million ≈ $1.73 Million |
-8.14% |
| 2021-12-31 | Skr17.50 Million ≈ $1.88 Million |
+205.68% |
| 2020-12-31 | Skr5.72 Million ≈ $616.10K |
-44.48% |
| 2019-12-31 | Skr10.31 Million ≈ $1.11 Million |
+177.43% |
| 2018-12-31 | Skr3.72 Million ≈ $399.95K |
+60.65% |
| 2017-12-31 | Skr2.31 Million ≈ $248.97K |
-33.76% |
| 2016-12-31 | Skr3.49 Million ≈ $375.87K |
+6027.54% |
| 2015-12-31 | Skr57.00K ≈ $6.13K |
-29.63% |
| 2014-12-31 | Skr81.00K ≈ $8.72K |
-- |
About SynAct Pharma AB
SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency. It is also developing TXP-11, an advanced peptide agonist … Read more